Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of TAK-079 (Mezagitamab) in Persistent/Chronic Primary Immune Thrombocytopenia
2019-004103-12Phase 2Completed
- Sponsor
- Takeda
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing TAK-079 (Mezagitamab) with Placebo (2 arms). Primary endpoint: Primary safety endpoint. Started Apr 2020; status: completed.
02
Drugs
mezagitamab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2019-004103-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004103-12.